Active Filter(s):
Details:
Trecondyv (treosulfan) is used to prepare patients for blood stem cell transplant. Trecondyv destroys bone marrow cells. This allows for the transplant of new blood stem cells from a donor which leads to the production of healthy blood cells.
Lead Product(s): Treosulfan,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: Trecondyv
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2022
Details:
Study found event-free survival and overall survival superior after Trecondyv (treosulfan) compared to RIC busulfan, also found non-relapse mortality lower in treosulfan arm than busulfan arm.
Lead Product(s): Treosulfan,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: Trecondyv
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Medac
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
Trecondyv (treosulfan), preparative regimen for allogeneic hematopoietic stem cell transplantation to be used in combination with fludarabine, is medication given to people before they have bone marrow transplant from a donor allogeneic hematopoietic stem cell transplantation
Lead Product(s): Treosulfan,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: Trecondyv
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2022
Details:
The resubmission includes additional clinical data and statistical analysis relating to previously-completed phase 3 clinical trial of Treosulfan as well as an update of integrated summary of safety, which FDA had requested in their July 2021 Complete Response Letter to medac.
Lead Product(s): Treosulfan,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: Treosulfan
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2022
Details:
Treosulfan will be marketed in Canada under the brand name Trecondyv® and indicated in combination with fludarabine as part of a conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (“allo-HSCT”).
Lead Product(s): Treosulfan,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: Trecondyv
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Medexus Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 12, 2021
Details:
Medac intends to leverage its strong, existing commercial infrastructure in the United States to address the underserved allo-HSCT market through its commercialization of treosulfan.
Lead Product(s): Treosulfan,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: Trecondi
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Medexus Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 02, 2021